A randomized, dose-finding, phase II study of the selective relaxant binding drug, sugammadex, capable of safely reversing profound rocuronium-lnduced neuromuscular blockGROUDINE, Scott B; SOTO, Roy; LIEN, Cynthia et al.Anesthesia and analgesia. 2007, Vol 104, Num 3, pp 555-562, issn 0003-2999, 8 p.Article

Differential Roles of Phase I and Phase II Enzymes in 3,4-Methylendioxymethamphetamine-Induced CytotoxicityANTOLINO-LOBO, Irene; MEULENBELT, Jan; NIJMEIJER, Sandra M et al.Drug metabolism and disposition. 2010, Vol 38, Num 7, pp 1105-1112, issn 0090-9556, 8 p.Article

Novel Designs and End Points for Phase II Clinical Trials : Phase II Trials: Designs for the futureADJEI, Alex A; CHRISTIAN, Michaele; IVY, Percy et al.Clinical cancer research (Print). 2009, Vol 15, Num 6, pp 1866-1872, issn 1078-0432, 7 p.Article

A two-stage design for a phase II clinical trial of coenzyme Q10 in ALSLEVY, G; KAUFMANN, P; THOMPSON, J. L. P et al.Neurology. 2006, Vol 66, Num 5, pp 660-663, issn 0028-3878, 4 p.Article

The unclear zone in phase II clinical trialsALLEGRO, Sabrina; POND, Gregory R; HOTTE, Sébastien J et al.European journal of cancer (1990). 2010, Vol 46, Num 13, pp 2408-2413, issn 0959-8049, 6 p.Article

Multiple Histology Phase II TrialsLEBLANC, Michael; RANKIN, Cathryn; CROWLEY, John et al.Clinical cancer research (Print). 2009, Vol 15, Num 13, pp 4256-4262, issn 1078-0432, 7 p.Article

A three-outcome design for phase II clinical trialsSARGENT, Daniel J; CHAN, Victor; GOLDBERG, Richard M et al.Controlled clinical trials. 2001, Vol 22, Num 2, pp 117-125, issn 0197-2456Article

Randomized phase II clinical trialsSIMON, R; WITTES, R. E; ELLENBERG, S. S et al.Cancer treatment reports. 1985, Vol 69, Num 12, pp 1375-1381, issn 0361-5960Article

Clinical drug development: an analysis of phase II trials, 1970-1985MARSONI, S; HOTH, D; SIMON, R et al.Cancer treatment reports. 1987, Vol 71, Num 1, pp 71-80, issn 0361-5960Article

Reversal of Profound, High-dose Rocuronium-induced Neuromuscular Blockade by Sugammadex at Two Different Time Points : An International, Multicenter, Randomized, Dose finding, Safety Assessor-blinded, Phase II TrialPUHRINGER, Friedrich K; REX, Christopher; SIELENKÄMPER, Andreas W et al.Anesthesiology (Philadelphia). 2008, Vol 109, Num 2, pp 188-197, issn 0003-3022, 10 p.Article

Safety and acceptability of the candidate microbicide Carraguard in Thai women : Findings from a phase II clinical trialKILMARX, Peter H; VAN DE WIJGERT, Janneke H. H. M; SUPAWITKUL, Somsak et al.Journal of acquired immune deficiency syndromes (1999). 2006, Vol 43, Num 3, pp 327-334, issn 1525-4135, 8 p.Article

Plans expérimentaux pour l'inclusion de patients dans les essais de phase II = Statisticals designs for phase II trialsKRAMAR, A; POTVIN, D; HILL, C et al.Revue d'épidémiologie et de santé publique. 1996, Vol 44, Num 4, pp 364-371, issn 0398-7620Article

Phase II Trials Powered to Detect Tumor SubtypesROBERTS, John D; RAMAKRISHNAN, Viswanathan.Clinical cancer research (Print). 2011, Vol 17, Num 17, pp 5538-5545, issn 1078-0432, 8 p.Article

Phase II Cancer Prevention Clinical Trials : Cancer prevention IISZABO, Eva.Seminars in oncology. 2010, Vol 37, Num 4, pp 359-366, issn 0093-7754, 8 p.Article

New designs for phase 2 clinical trialsESTEY, Elihu H; THALL, Peter F.Blood. 2003, Vol 102, Num 2, pp 442-448, issn 0006-4971, 7 p.Article

Phase I trial of taxotere : five-day schedulePAZDUR, R; NEWMAN, R. A; RABER, M. N et al.Journal of the National Cancer Institute. 1992, Vol 84, Num 23, pp 1781-1788, issn 0027-8874Article

A phase II, double-blind, placebo-controlled, ascending-dose study of eritoran (E5564), a upid a antagonist, in patients undergoing cardiac surgery with cardiopulmonary bypassBENNETT-GUERRERO, Elliott; GROCOTT, Hilary P; LEVY, Jerrold H et al.Anesthesia and analgesia. 2007, Vol 104, Num 2, pp 378-383, issn 0003-2999, 6 p.Article

Setting the bar in phase II trials : The use of historical data for determining Go/No Go decision for definitive phase III testing. CommentaryVICKERS, Andrew J; BALLEN, Vennus; SCHER, Howard I et al.Clinical cancer research. 2007, Vol 13, Num 3, issn 1078-0432, 781-782, 972-976 [8 p.]Article

Bayesian sample size calculations in phase II clinical trials using informative conjugate priorsMAYO, Matthew S; GAJEWSKI, Byron J.Controlled clinical trials. 2004, Vol 25, Num 2, pp 157-167, issn 0197-2456, 11 p.Article

Resampling Phase III Data to Assess Phase II Trial Designs and EndpointsSHARMA, Manish R; KARRISON, Theodore G; YUYAN JIN et al.Clinical cancer research (Print). 2012, Vol 18, Num 8, pp 2309-2315, issn 1078-0432, 7 p.Article

Randomized controlled phase II trial of glatiramer acetate in ALSGORDON, P. H; DOORISH, C; GENDELMAN, H. E et al.Neurology. 2006, Vol 66, Num 7, pp 1117-1119, issn 0028-3878, 3 p.Article

Guidelines for assessing the performance of statisticians involved in clinical research in the pharmaceutical industryPHILLIPS, A.Drug information journal. 1999, Vol 33, Num 2, pp 427-433, issn 0092-8615Conference Paper

Etoposide for epidemic Kaposi's sarcoma: a phase II studyBAKKER, P. J. M; DANNER, S. A; LANGE, J. M. A et al.European journal of cancer & clinical oncology. 1988, Vol 24, Num 6, pp 1047-1048, issn 0277-5379Article

Randomized Phase II Trials: Inevitable or Inadvisable?GAN, Hui K; GROTHEY, Axel; POND, Gregory R et al.Journal of clinical oncology. 2010, Vol 28, Num 15, pp 2641-2647, issn 0732-183X, 7 p.Article

A Comparison of Phase II Study StrategiesHUNSBERGER, Sally; YINGDONG ZHAO; SIMON, Richard et al.Clinical cancer research (Print). 2009, Vol 15, Num 19, pp 5950-5955, issn 1078-0432, 6 p.Article